Insta
India Joins WHO’s ‘Solidarity Trials’ Of Anti-Ebola Remdesivir, Other Drugs Against Covid-19
Swarajya Staff
Apr 14, 2020, 10:56 AM | Updated 10:56 AM IST
Save & read from anywhere!
Bookmark stories for easy access on any device or the Swarajya app.
India has joined the World Health Organisation (WHO)'s solidarity trials for the drug Remdesivir which had shown promising results in the treatment of Covid-19 patients needing enhanced oxygen and ventilator support, reports Times of India.
Being a member of the WHO trials, India will be able to access the benefits which arise out of it, if and when the medication is established for the treatment of Covid-19 in clinical use. The clinical trials of the drug are however still to begin.
Remdesivir drug was developed to be effective in the fight against Ebola and has shown significant benefits for two-thirds of patients with severe symptoms during the use on a set of patients in the United States (US), Canada, Europe and Japan, who were able to thereafter get off oxygen and ventilator support.
The development was made public by the Indian Council of Medical Research (ICMR)'s Dr Raman Gangakhedkar during the Union Ministry of Health and Family Welfare (MoHFW)'s daily briefing on Monday (13 April). Meanwhile, it should be noted that the WHO's solidarity trials are also working to analyse the efficacy of other drugs against Covid-19.
Save & read from anywhere!
Bookmark stories for easy access on any device or the Swarajya app.
Introducing ElectionsHQ + 50 Ground Reports Project
The 2024 elections might seem easy to guess, but there are some important questions that shouldn't be missed.
Do freebies still sway voters? Do people prioritise infrastructure when voting? How will Punjab vote?
The answers to these questions provide great insights into where we, as a country, are headed in the years to come.
Swarajya is starting a project with an aim to do 50 solid ground stories and a smart commentary service on WhatsApp, a one-of-a-kind. We'd love your support during this election season.
Click below to contribute.